A Phase 2 interventional study of GLP-1/FGF21 dual agonist (HEC88473) in PCOS (Polycystic Ovary Syndrome), sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Shanghai Zhongshan Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Polycystic Ovary Syndrome with a site in China — 29 open to participants now, 33 under way, none of them phase 3. Polycystic Ovary Syndrome · China.
Among the 107 studies in Polycystic Ovary Syndrome with a site in China, this one is the 81st largest by planned enrollment of the 86 interventional ones that give a count, is one of 7 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 22 of the 32 other live ones, and was the 99th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →29 of the 107 studies in Polycystic Ovary Syndrome with a site in China are open now. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–40 · Women only · Healthy volunteers
Shanghai First Maternity and Infant Hospital · Sites in China
Ages 19–40 · Women only
Sichuan Provincial People's Hospital · Sites in China
Ages 18–40 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 12 · Phase 3 7 · Phase 4 14
First in 2008; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 100 across the 86 interventional studies, 300 across the 21 observational. Of the 37 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 107 have an industry lead sponsor. The 10 most frequent:
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
Shanghai Zhongshan Hospital has 5 studies filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Polycystic Ovary Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07739940Guangdong Women and Children HospitalClinical Research Cohort for Polycystic Ovary Syndrome | 2026-12-01 |
| NCT07739953Guangdong Women and Children HospitalDevelopment and Clinical Application of ApoC3 Protein as a Predictive Biomarker for Insulin Resistance in Polycystic Ovary Syndrome | 2026-12-31 |
| NCT06775093Peking University Third HospitalEffects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | 2026-12-31 |
| NCT07616037Shanghai Zhongshan HospitalEfficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 107 studies in Polycystic Ovary Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine and metabolic disorder among women of reproductive age. It is characterized by oligo-ovulation or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology. In addition, PCOS is frequently accompanied by multiple metabolic abnormalities, including insulin resistance, obesity, impaired glucose tolerance, and dyslipidemia. Clinical studies have demonstrated that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in women with PCOS results in significant weight reduction, decreased free testosterone levels, improvement in menstrual regularity, and increased clinical pregnancy rates. Fibroblast growth factor 21 (FGF21) has been shown to enhance insulin sensitivity, promote fatty acid oxidation, and improve lipid distribution.
HEC88473 is a novel long-acting dual agonist targeting both the glucagon-like peptide-1 (GLP-1) receptor and the fibroblast growth factor 21 (FGF21) receptor. This study is initiated to evaluate the clinical efficacy of HEC88473 in women with PCOS and to explore its potential as a new therapeutic option for the management of PCOS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Fulfillment of at least two of the diagnostic criteria for PCOS according to the 2023 International Guideline, including:
Irregular menstrual cycles:
1-3 years after menarche: cycle length \<21 days or >45 days; ≥3 years after menarche to perimenopause: cycle length \<21 days or >35 days, or fewer than 8 menstrual cycles per year; ≥1 year after menarche: any cycle >90 days;
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To evaluate the longitudinal changes in androgen metabolism in women with polycystic ovary syndrome (PCOS) during treatment with the GLP-1/FGF21 dual agonist HEC88473.
Drug: GLP-1/FGF21 dual agonist (HEC88473)
Drug page: Glucagon-Like Peptide 1Studies of Glucagon-Like Peptide 1Glucagon-Like Peptide 1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
GLP-1/FGF21 dual agonist (HEC88473) will be administered by subcutaneous injection once weekly. The starting dose is 15 mg for 3 consecutive weeks. If well tolerated, the dose will be escalated to 30 mg for an additional 3 weeks, followed by further escalation to 45 mg for 18 weeks, provided tolerability is maintained.
Change From Baseline in Free Androgen Index Over 24 Weeks of Treatment
Longitudinal changes in free androgen index from baseline at each scheduled follow-up visit during the 24-week treatment period.
Time frame: Baseline to Week 24 (assessed at scheduled follow-up visits).
Change in the Number of Spontaneous Menstrual Cycles During the 24-Week Treatment Period Compared With the 24-Week Pre-treatment Period
Comparison of the number of spontaneous menstrual cycles during the 24-week intervention period with those during the 24-week period prior to treatment initiation.
Time frame: 24 weeks before treatment initiation to 24 weeks after treatment initiation.
Change From Baseline in Bilateral Antral Follicle Count (Diameter <10 mm) at Week 24
Change from baseline in the total number of antral follicles with a diameter \<10 mm in both ovaries after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Bilateral Ovarian Volume at Week 24
Change from baseline in the total ovarian volume of both ovaries after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Serum AMH at Week 24
Change from baseline in serum levels of anti-Müllerian hormone (AMH) after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Serum Total Testosterone at Week 24
Change from baseline in serum levels of total testosterone after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Serum DHEA-S at Week 24
Change from baseline in serum levels of dehydroepiandrosterone sulfate (DHEA-S) after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Serum SHBG at Week 24
Change from baseline in serum levels of sex hormone-binding globulin (SHBG) after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in HOMA IR Index at Week 24
Change from baseline in insulin resistance assessed by the HOMA Insulin Resistance index (calculated from fasting plasma glucose in mmol/L × fasting serum insulin in μU/mL/22.5) after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Lipid Profile at Week 24
Change from baseline in serum lipid profile after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Body Weight at Week 24
Change from baseline in body weight after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Waist Circumference at Week 24
Change from baseline in waist circumference after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Quality of Life Assessed by SF-36 at Week 24
Change from baseline in quality of life evaluated using the Short Form-36 (SF-36) after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Change From Baseline in Quality of Life Assessed by PCOSQ at Week 24
Change from baseline in quality of life evaluated using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) after 24 weeks of treatment.
Time frame: Baseline to Week 24.
Incidence and Severity of Adverse Events During the 24-Week Treatment Period
Assessment of the incidence, type, and severity of adverse events occurring during the 24-week treatment period.
Time frame: Baseline to Week 24.
Plan to share: Yes
Supporting information: Study protocol
Time frame: After publication.
Access criteria: IPD and supporting information will be available to researchers upon reasonable request (e.g., with a practical and meaningful research proposal).
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
Of 23 phase 2 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glucagon-Like Peptide 1